18.0 Abstract: Tumor Immunology and Immunotherapy Program The overarching goal of the Tumor Immunology and Immunotherapy (TII) Program of UMGCC is to develop and implement immune-based strategies to prevent, treat, and/or monitor malignant diseases and disease progression. To achieve this goal, the program focuses on three specific aims: Theme 1: Cell-based cancer immunotherapies?elicit active tumor immunity capable of reducing or preventing malignant cell growth; Theme 2: Inhibiting immunosuppression?develop strategies to overcome tumor immune evasion; and Theme 3: Cancer and inflammation?elucidate the roles for infection and inflammatory responses in cancer development. The successful implementation of this work is facilitated by strong interactions between clinicians and basic researchers. Program research and mentoring strategies are designed to promote inter- and intraprogrammatic interaction and mentoring of junior research and clinical faculty. The TII program has 60 members representing 17 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $4.1 million total annual funding, including $0.6 million from NCI and $2.6 million from other peer-reviewed sources. In addition, TII Program members receive $0.9 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, TII members authored 366 cancer-related publications, of which 21 percent resulted from intraprogrammatic and 22 percent from interprogrammatic collaborations. Approximately 52 percent of the publications represent collaborations with external investigators. Research efforts by TII faculty are supported by extensive use of the FCSS, BSS, and PBSS.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423
McCusker, Michael G; El Chaer, Firas; Duffy, Alison et al. (2018) Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia. Am J Leuk Res 2:
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546

Showing the most recent 10 out of 257 publications